SmartBreast™ Acquires Molecular Breast Imaging Assets from Dilon Technologies®
News provided by
Share this article
PITTSBURGH, Dec. 29, 2020 /PRNewswire/
Smart Breast Corporation (SmartBreast™), a privately held company focused on breast cancer screening and detection, announced today that it has acquired certain Molecular Breast Imaging (MBI) assets from Dilon Technologies, Inc. (Dilon) for an undisclosed amount.
Dilon D6800 MBI scanner acquired by SmartBreast.
Comparison of mammogram in dense breast tissue that appeared “normal” and the MBI scan which detects a hidden early stage invasive cancer (courtesy of Mayo Clinic).
The acquired MBI technology sees through dense breast tissue to find 3 to 4 times more cancers than mammography alone.